ofloxacin and Pseudomonas Infections studies

Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

Research Excerpts

Excerpt	Relevance	Reference
"These study results indicate that levofloxacin 250 mg orally once daily for 10 days is an effective and well tolerated treatment of complicated urinary tract infections."	9.10	[Multicentric study for evaluation of levofloxacin in the treatment of complicated urinary tract infections]. ( Marchetti, F; Trinchieri, A, 2003)
"The experience with lomefloxacin and ofloxacin respectively in the complex therapy of 26 and 40 patients with burns is described."	9.08	[Efficacy of lomefloxacin and ofloxacin in complex therapy of infections in patients with burns]. ( Alekseev, AA; Bobrovnikov, AE; Elagina, LV; Grishina, IA; Iakovlev, VP; Izotova, GN; Krutikov, MG, 1998)
"The clinical efficacy and safety of ciprofloxacin and ofloxacin were compared in a prospective, randomized double blind, placebo combined cross-over study in 26 adult cystic fibrosis patients with chronic broncho-pulmonary Pseudomonas aeruginosa infection."	9.06	The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. ( Høiby, N; Jensen, T; Koch, C; Nielsen, CH; Pedersen, SS, 1987)
"The steady state pharmacokinetic properties of ciprofloxacin and ofloxacin were compared in cystic fibrosis patients."	9.06	Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. ( Hvidberg, EF; Jensen, T; Pedersen, SS, 1987)
"We evaluated, by Monte Carlo simulation, 500-mg once-daily, 100-mg thrice-daily, 200-mg twice-daily, and 200-mg thrice-daily dose regimens of levofloxacin (LVFX), for the ratio of area under the concentration-time curve for 24 h (AUC(0-24)) to minimum inhibitory concentration (MIC) (AUC(0-24)/MIC) and the ratio of maximum plasma concentration (C(max)) to MIC (C(max)/MIC), which predict microbiological outcomes, and the C(max)/MIC, which inhibits fluoroquinolone resistance selection, in complicated urinary tract infections (UTIs) with Escherichia coli or Pseudomonas aeruginosa."	7.77	Evaluation by Monte Carlo simulation of levofloxacin dosing for complicated urinary tract infections caused by Escherichia coli or Pseudomonas aeruginosa. ( Deguchi, T; Matsumoto, T; Seike, K; Yasuda, M, 2011)
" epidermidis endophthalmitis model, levofloxacin treatment produced an approximately 3 log decrease in CFU/ml of vitreous relative to that in untreated eyes (p = 0."	7.74	Bactericidal effect of intravitreal levofloxacin in an experimental model of endophthalmitis. ( Abad, JL; Alió, JL; Fernandez, J; Ferrer, C; Rodríguez, A, 2008)
"The therapeutic activity of ciprofloxacin, enoxacin, and ofloxacin was evaluated in guinea pigs with acute and chronic experimental Pseudomonas aeruginosa pneumonia."	7.67	Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa pneumonia. ( Kemmerich, B; Pennington, JE; Small, GJ, 1986)
"The chemotherapeutic efficacy of ofloxacin against experimental pneumonia was investigated with special reference to its treatment regimen."	7.67	Chemotherapeutic efficacy of ofloxacin against experimental pneumonia with Pseudomonas aeruginosa in guinea pigs. ( Hashimoto, S; Iigo, Y; Ishida, Y; Nakajima, R; Osada, Y; Otani, T; Une, T, 1989)
" Standard levofloxacin dosing (especially monotherapy) is unlikely to produce maximum therapeutic effectiveness."	6.73	Levofloxacin pharmacokinetics in adult cystic fibrosis. ( Boyle, MP; Brass-Ernst, L; Diener-West, M; Lee, CKK; Noschese, M; Zeitlin, PL, 2007)
"Bacterial keratitis is a serious infectious ocular disease requiring prompt treatment to prevent frequent and severe visual disabilities."	5.32	A mucoadhesive polymer extracted from tamarind seed improves the intraocular penetration and efficacy of rufloxacin in topical treatment of experimental bacterial keratitis. ( Boldrini, E; Campa, M; Celandroni, F; Davini, P; Ghelardi, E; Parisio, E; Salvetti, S; Senesi, S; Tavanti, A, 2004)
"These study results indicate that levofloxacin 250 mg orally once daily for 10 days is an effective and well tolerated treatment of complicated urinary tract infections."	5.10	[Multicentric study for evaluation of levofloxacin in the treatment of complicated urinary tract infections]. ( Marchetti, F; Trinchieri, A, 2003)
"The experience with lomefloxacin and ofloxacin respectively in the complex therapy of 26 and 40 patients with burns is described."	5.08	[Efficacy of lomefloxacin and ofloxacin in complex therapy of infections in patients with burns]. ( Alekseev, AA; Bobrovnikov, AE; Elagina, LV; Grishina, IA; Iakovlev, VP; Izotova, GN; Krutikov, MG, 1998)
"The clinical efficacy and safety of ciprofloxacin and ofloxacin were compared in a prospective, randomized double blind, placebo combined cross-over study in 26 adult cystic fibrosis patients with chronic broncho-pulmonary Pseudomonas aeruginosa infection."	5.06	The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. ( Høiby, N; Jensen, T; Koch, C; Nielsen, CH; Pedersen, SS, 1987)
"The steady state pharmacokinetic properties of ciprofloxacin and ofloxacin were compared in cystic fibrosis patients."	5.06	Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. ( Hvidberg, EF; Jensen, T; Pedersen, SS, 1987)
"We evaluated, by Monte Carlo simulation, 500-mg once-daily, 100-mg thrice-daily, 200-mg twice-daily, and 200-mg thrice-daily dose regimens of levofloxacin (LVFX), for the ratio of area under the concentration-time curve for 24 h (AUC(0-24)) to minimum inhibitory concentration (MIC) (AUC(0-24)/MIC) and the ratio of maximum plasma concentration (C(max)) to MIC (C(max)/MIC), which predict microbiological outcomes, and the C(max)/MIC, which inhibits fluoroquinolone resistance selection, in complicated urinary tract infections (UTIs) with Escherichia coli or Pseudomonas aeruginosa."	3.77	Evaluation by Monte Carlo simulation of levofloxacin dosing for complicated urinary tract infections caused by Escherichia coli or Pseudomonas aeruginosa. ( Deguchi, T; Matsumoto, T; Seike, K; Yasuda, M, 2011)
"To compare the therapeutic effectiveness of a single intrastromal dose of gentamycin, tobramycin, ciprofloxacin and ofloxacin for the treatment of corneal ulcers due to Pseudomonas aeruginosa."	3.75	[Bacterial corneal ulcer treated with intrastromal antibiotic. Experimental model in vivo]. ( Naranjo-Tackman, R; Stangogiannis-Druya, C; Stangogiannis-Druya, E; Vanzzini, V; Villar-Kurí, J, 2009)
" epidermidis endophthalmitis model, levofloxacin treatment produced an approximately 3 log decrease in CFU/ml of vitreous relative to that in untreated eyes (p = 0."	3.74	Bactericidal effect of intravitreal levofloxacin in an experimental model of endophthalmitis. ( Abad, JL; Alió, JL; Fernandez, J; Ferrer, C; Rodríguez, A, 2008)
"Overall, moxifloxacin was the most effective of the four fluoroquinolones in reducing CFU/cornea in the rabbit model of gram-negative keratitis."	3.72	Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis. ( Caballero, AR; Dajcs, JJ; Girgis, DO; Marquart, ME; O'Callaghan, RJ; Thibodeaux, BA, 2004)
"To explore the effects of Zhikuofang, a TCM prescription, and Ofloxacin on the inflammation and cytostatics of the airway model of bronchiectasis."	3.71	[Effects of the zhikuofang on the inflammation and cytostatics of the airway model of bronchiectasis]. ( Bi, JJ; Cao, SH; Wan, YG; Zhou, M; Zhou, Y; Zhu, YH, 2002)
" The combined effects of ovoM and the new quinolone, ofloxacin (OFLX) on experimental Pseudomonas aeruginosa keratitis were investigated."	3.69	Therapeutic intervention with chicken egg white ovomacroglobulin and a new quinolone on experimental Pseudomonas keratitis. ( Kamata, R; Maeda, H; Matsumoto, K; Miyagawa, S; Okamura, R, 1994)
"The antibacterial activity of ofloxacin, a new gyrase inhibitor, was tested in experimental acute occlusive pyelonephritis in rats caused by Escherichia coli O4:H5 and Pseudomonas aeruginosa A 9532."	3.67	[Results of ofloxacin treatment of experimental urinary tract infections]. ( Ritzerfeld, W, 1986)
"The therapeutic activity of ciprofloxacin, enoxacin, and ofloxacin was evaluated in guinea pigs with acute and chronic experimental Pseudomonas aeruginosa pneumonia."	3.67	Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa pneumonia. ( Kemmerich, B; Pennington, JE; Small, GJ, 1986)
"The chemotherapeutic efficacy of ofloxacin against experimental pneumonia was investigated with special reference to its treatment regimen."	3.67	Chemotherapeutic efficacy of ofloxacin against experimental pneumonia with Pseudomonas aeruginosa in guinea pigs. ( Hashimoto, S; Iigo, Y; Ishida, Y; Nakajima, R; Osada, Y; Otani, T; Une, T, 1989)
" Standard levofloxacin dosing (especially monotherapy) is unlikely to produce maximum therapeutic effectiveness."	2.73	Levofloxacin pharmacokinetics in adult cystic fibrosis. ( Boyle, MP; Brass-Ernst, L; Diener-West, M; Lee, CKK; Noschese, M; Zeitlin, PL, 2007)
"Levofloxacin was administered as an infusion of 500 mg/h for 1."	2.71	Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. ( Corrado, M; Drusano, GL; Fowler, C; Kahn, J; Preston, SL; Weisinger, B, 2004)
" Despite the antipseudomonal advantage noted for ciprofloxacin monotherapy, it is unknown whether this advantage is maintained when the fluoroquinolones are used in combination with antipseudomonal beta-lactams such as ceftazidime and piperacillin."	2.68	Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa. ( Klepser, ME; Nicolau, DP; Nightingale, CH; Patel, KB; Quintiliani, R, 1995)
"Ofloxacin therapy was administered an average of 45 days per patient, and was well tolerated."	2.67	Oral ofloxacin for infections caused by bacteria resistant to oral antimicrobial agents. ( Eron, LJ; Gentry, LO, 1992)
" Older literature supports an oral dosing regimen of 40 mg/kg/day divided every 12 hr, up to 2 g/day, and intravenous (IV) ciprofloxacin 30 mg/kg/day divided every 8 hr, maximum 1."	2.49	Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones. ( Ampofo, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Waters, CD; Young, DC; Zobell, JT, 2013)
"For levofloxacin-treated CAP patients with P."	2.43	Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience. ( Davis, NB; Kahn, J; Tennenberg, AM; Wu, SC, 2006)
"Here, a case of infectious mid basilar artery aneurysm from Pseudomonas meningitis, and its angiographic remission from timely antibiotic therapy, is reported."	1.38	Infectious mid basilar artery aneurysm from Pseudomonas meningitis. ( Flores, B; Rickert, K; Samson, D; Yu, W, 2012)
"Gentamicin resistance was associated with previous administration of a penicillin."	1.37	Risk factors for bacteraemia attributable to Pseudomonas aeruginosa resistant to imipenem, levofloxacin, or gentamicin. ( Goto, H; Higaki, M; Honda, K; Ishii, H; Mikura, S; Nakamura, M; Okazaki, M; Tsunoda, T; Wada, H; Watanabe, T; Yasutake, T, 2011)
"New approaches are needed for the treatment of Pseudomonas aeruginosa infections."	1.36	The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression. ( Bahniuk, N; Brown, DL; Drusano, GL; Grasso, C; Kulawy, R; Louie, A; Van Scoy, B, 2010)
"Levofloxacin 1."	1.36	Topical levofloxacin 1.5% overcomes in vitro resistance in rabbit keratitis models. ( Gordon, YJ; Kowalski, RP; Mah, FS; Romanowski, EG; Shanks, RM, 2010)
"Levofloxacin seems to be a good alternative treatment for patients with uncomplicated spontaneous ascites infections."	1.36	A recent evaluation of empirical cephalosporin treatment and antibiotic resistance of changing bacterial profiles in spontaneous bacterial peritonitis. ( Alişkan, H; Güçlü, M; Husamettin, E; Serin, E; Yakar, T, 2010)
"Levofloxacin use was associated with increased resistance of P."	1.36	Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use. ( Chun, CL; Hsueh, PR; Lee, YJ; Lin, YC; Liu, HY; Sun, KL, 2010)
" aeruginosa biofilm and the shedding planktonic cells in response to different ofloxacin dosing regimens were not parallel and this may explain the non-coincidence of microbiological and clinical outcomes with biofilm associated infections."	1.35	Novel in vitro pharmacodynamic model simulating ofloxacin pharmacokinetics in the treatment of Pseudomonas aeruginosa biofilm-associated infections. ( Elkhatib, WF; Noreddin, AM, 2009)
" The superiority of aerosol dosing over systemic dosing was demonstrated in models of both acute and chronic lung infection."	1.35	Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. ( Dudley, MN; Griffith, DC; Miller, CE; Nolan, TG; Sabet, M; Senekeo-Effenberger, K, 2009)
"Facial paralysis was present in 19."	1.34	Necrotizing external otitis: a report of 46 cases. ( Bebear, C; Blanchet, H; Darrouzet, V; Dutronc, H; Franco-Vidal, V, 2007)
"Nosocomial pneumonia is a severe complication after cardiac surgery (CS)."	1.33	In vivo measurement of levofloxacin penetration into lung tissue after cardiac surgery. ( Burgmann, H; Hutschala, D; Jaksch, P; Mayer-Helm, BX; Müller, M; Skhirtladze, K; Tschernko, EM; Wisser, W; Wolner, E; Zuckermann, A, 2005)
" CAZ combined with LVX or AMK yielded Fls indicating synergism (Fl < or = 0."	1.33	In vitro and in vivo synergy of levofloxacin or amikacin both in combination with ceftazidime against clinical isolates of Pseudomonas aeruginosa. ( Felici, A; Guerrini, M; Marchetti, F; Piccoli, L, 2005)
"Pseudomonas aeruginosa infections have been associated with considerable morbidity and mortality."	1.33	Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. ( Bilker, WB; Fishman, NO; Gasink, LB; Lautenbach, E; Nachamkin, I; Weiner, MG, 2006)
"Levofloxacin use was more frequent in the QR P."	1.33	Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa. ( Carmeli, Y; Dodds, AE; Engemann, JJ; Kanafani, ZA; Kaye, KS; Weber, SG, 2006)
"Acute epididymo-orchitis is a common cause of 'acute scrotum' in adolescence and young adults, and the common causative pathogens are Chlamydia trachomatis and Neisseria gonorrhoeae."	1.32	Pseudomonas orchitis in puberty. ( Rajagopal, AS, 2004)
"Bacterial keratitis is a serious infectious ocular disease requiring prompt treatment to prevent frequent and severe visual disabilities."	1.32	A mucoadhesive polymer extracted from tamarind seed improves the intraocular penetration and efficacy of rufloxacin in topical treatment of experimental bacterial keratitis. ( Boldrini, E; Campa, M; Celandroni, F; Davini, P; Ghelardi, E; Parisio, E; Salvetti, S; Senesi, S; Tavanti, A, 2004)
" Dosing regimens and consequent drug exposures that amplify or suppress the emergence of resistant bacterial subpopulations were identified and prospectively validated."	1.32	Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. ( Bachhawat, R; Bush, K; Deziel, MR; Drusano, GL; Dudley, MN; Freeman, C; Jumbe, N; Kahn, JB; Leary, R; Liu, W; Louie, A; Miller, MH; Tam, VH, 2003)
" This study evaluated the in vitro activity of two concentrations of levofloxacin (modeled for the 500 mg and 750 mg daily dose) in combination with ceftazidime, cefepime, piperacillin/tazobactam, imipenem, and tobramycin against P."	1.32	In vitro evaluation of the activity of two doses of Levofloxacin alone and in combination with other agents against Pseudomonas aeruginosa. ( Burgess, DS; Hall, RG; Hardin, TC, 2003)
"Although Pseudomonas infections in post-RK eyes have been reported, late-onset Pseudomonas keratitis in a patient with four radial incisions and no history of contact lens wear is contrary to previous reports."	1.30	Delayed-onset Pseudomonas keratitis after radial keratotomy. ( Procope, JA, 1997)
" Test fluoroquinolones were administered orally at 1 h (single dose) or at 1 and 3 h (divided dose) postinfection, with 10 infected mice used for each of six concentrations of each fluoroquinolone tested (1 to 40 mg/kg of body weight) in each dosing regimen."	1.29	In vivo oral efficacy of levofloxacin for treatment of systemic Pseudomonas aeruginosa infections in a murine model of septicemia. ( Amaratunga, DJ; Barrett, JF; Frosco, MB; Yagel, SK, 1996)
"Acute suppurative parotitis is a rare infection which usually occurs in hospitalized patients."	1.29	[Acute suppurative parotitis caused by Pseudomonas aeruginosa]. ( Mouallem, M; Regev, G, 1994)
"Ofloxacin and enoxacin were administered per os and pefloxacin and ciprofloxacin were injected subcutaneously."	1.28	[Activity of fluoroquinolones studied on a model of suppurative meningoencephalitis caused by Pseudomonas aeruginosa in mice]. ( Mnatsakanian, VE; Padeĭskaia, EN, 1991)
"Among 219 pathogens originating from nosocomial infections, 3."	1.27	Comparative activity of ofloxacin with reference to bacterial strains isolated in in-patients and out-patients. ( Alkan, M; Berger, S; Bogokowski, B; Keren, G; Mark, Z; Rubinstein, E, 1986)

Research

Studies (132)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Change in FEV1 Percent Predicted

Timeframe	Studies, this research(%)	All Research%
pre-1990	17 (12.88)	18.7374
1990's	31 (23.48)	18.2507
2000's	55 (41.67)	29.6817
2010's	28 (21.21)	24.3611
2020's	1 (0.76)	2.80

Authors	Studies
Segawa, J	1
Kitano, M	1
Kazuno, K	1
Matsuoka, M	1
Shirahase, I	1
Ozaki, M	1
Matsuda, M	1
Tomii, Y	1
Kise, M	1
Miyamoto, T	1
Matsumoto, J	1
Chiba, K	1
Egawa, H	1
Shibamori, K	1
Minamida, A	1
Nishimura, Y	1
Okada, H	1
Kataoka, M	1
Fujita, M	1
Khalil, H	1
Chen, T	1
Riffon, R	1
Wang, R	1
Wang, Z	1
Sugimura, M	1
Maseda, H	1
Hanaki, H	1
Nakae, T	1
Tanimoto, K	1
Tomita, H	1
Fujimoto, S	1
Okuzumi, K	1
Ike, Y	1
Khomtchouk, KM	1
Joseph, LI	1
Khomtchouk, BB	1
Kouhi, A	1
Massa, S	1
Xia, A	1
Koliesnik, I	1
Pletzer, D	1
Bollyky, PL	1
Santa Maria, PL	1
Gan, CW	1
Chooi, WH	1
Ng, HC	1
Wong, YS	1
Venkatraman, SS	1
Lim, LH	1
Tran, T	1
Samarawickrama, C	1
Petsoglou, C	1
Watson, S	1
Giovagnoli, S	1
Mancuso, F	1
Vannini, S	1
Calvitti, M	1
Piroddi, M	1
Pietrella, D	1
Arato, I	1
Falabella, G	1
Galli, F	1
Moretti, M	1
Neri, LM	1
Bodo, M	1
Capitani, S	1
Cameron, DF	1
Ricci, M	1
Luca, G	1
Calafiore, R	1
Fernandes, M	1
Vira, D	1
Medikonda, R	1
Kumar, N	1
Rasool, MH	1
Siddique, AB	1
Saqalein, M	1
Asghar, MJ	1
Zahoor, MA	1
Aslam, B	1
Shafiq, HB	1
Nisar, MA	1
Ullah, O	1
Khan, A	1
Ambreen, A	1
Ahmad, I	1
Akhtar, T	1
Gandapor, AJ	1
Khan, AM	1
Möllmann, U	1
Heinisch, L	1
Bauernfeind, A	1
Köhler, T	1
Ankel-Fuchs, D	1
Stangogiannis-Druya, E	1
Stangogiannis-Druya, C	1
Naranjo-Tackman, R	1
Vanzzini, V	1
Villar-Kurí, J	1
Louie, A	3
Fregeau, C	1
Liu, W	2
Kulawy, R	2
Drusano, GL	5
Yakar, T	1
Güçlü, M	1
Serin, E	1
Alişkan, H	1
Husamettin, E	1
Sabet, M	1
Miller, CE	1
Nolan, TG	1
Senekeo-Effenberger, K	1
Dudley, MN	3
Griffith, DC	2
Guss, J	1
Abuzeid, WM	1
Doghramji, L	1
Edelstein, PH	1
Chiu, AG	1
King, P	1
Citron, DM	1
Lomovskaya, O	1
Lee, YJ	1
Liu, HY	1
Lin, YC	1
Sun, KL	1
Chun, CL	1
Hsueh, PR	1
Grasso, C	1
Bahniuk, N	1
Van Scoy, B	1
Brown, DL	1
Kowalski, RP	1
Romanowski, EG	1
Mah, FS	1
Shanks, RM	1
Gordon, YJ	1
Hekiert, AM	1
Cohen, MB	1
Montone, KT	1
Palmer, JN	1
Govindaraj, S	1
Noreddin, AM	1
Elkhatib, WF	1
Konstantopoulos, A	1
Yadegarfar, G	1
Fievez, M	1
Anderson, DF	1
Hossain, P	1
Romero, VL	1
Manzo, RH	1
Alovero, FL	1
Deguchi, T	1
Seike, K	1
Yasuda, M	1
Matsumoto, T	1
Geller, DE	1
Flume, PA	1
Staab, D	1
Fischer, R	1
Loutit, JS	1
Conrad, DJ	1
Mikura, S	1
Wada, H	1
Okazaki, M	1
Nakamura, M	1
Honda, K	1
Yasutake, T	1
Higaki, M	1
Ishii, H	1
Watanabe, T	1
Tsunoda, T	1
Goto, H	1
Zheng, X	1
Kodama, T	1
Goto, T	1
Ohashi, Y	1
Sonnet, P	1
Izard, D	1
Mullié, C	1
Yu, W	1
Rickert, K	1
Flores, B	1
Samson, D	1
Nguyen, D	1
Joshi-Datar, A	1
Lepine, F	1
Bauerle, E	1
Olakanmi, O	1
Beer, K	1
McKay, G	1
Siehnel, R	1
Schafhauser, J	1
Wang, Y	1
Britigan, BE	1
Singh, PK	1
Lim, TP	1
Lee, W	1
Tan, TY	1
Sasikala, S	1
Teo, J	1
Hsu, LY	1
Tan, TT	1
Syahidah, N	1
Kwa, AL	1
Mori, N	1
Ishii, Y	1
Tateda, K	1
Kimura, S	1
Kouyama, Y	1
Inoko, H	1
Mitsunaga, S	1
Yamaguchi, K	1
Yoshihara, E	1
Gharabaghi, MA	1
Abdollahi, SM	1
Safavi, E	1
Abtahi, SH	1
Fernández-Olmos, A	1
García-Castillo, M	1
Maiz, L	1
Lamas, A	1
Baquero, F	1
Cantón, R	1
Stockmann, C	1
Sherwin, CM	1
Zobell, JT	1
Young, DC	1
Waters, CD	1
Spigarelli, MG	1
Ampofo, K	1
Keren, I	1
Mulcahy, LR	1
Lewis, K	1
Azoicai, D	1
Antoniu, SA	1
Erdem, I	1
Kaynar-Tascioglu, J	1
Kaya, B	1
Goktas, P	1
Trinchieri, A	1
Marchetti, F	3
Wan, YG	1
Cao, SH	1
Bi, JJ	1
Zhu, YH	1
Zhou, Y	1
Zhou, M	1
Burgess, DS	1
Hall, RG	1
Hardin, TC	1
Jumbe, N	1
Leary, R	1
Deziel, MR	1
Tam, VH	1
Bachhawat, R	1
Freeman, C	1
Kahn, JB	1
Bush, K	1
Miller, MH	1
Paladino, JA	1
Sunderlin, JL	1
Forrest, A	1
Schentag, JJ	1
Viale, P	1
Lee, EJ	1
Truong, TN	1
Mendoza, MN	1
Fleiszig, SM	1
Zeitlinger, MA	1
Dehghanyar, P	1
Mayer, BX	1
Schenk, BS	1
Neckel, U	1
Heinz, G	1
Georgopoulos, A	1
Müller, M	2
Joukhadar, C	1
Barequet, IS	1
Denton, P	1
Osterhout, GJ	1
Tuli, S	1
O'Brien, TP	1
Sahm, DF	1
Thornsberry, C	1
Jones, ME	1
Karlowsky, JA	1
De Vecchi, E	1
Drago, L	1
Nicola, L	1
Colombo, A	1
Guerra, A	1
Tocalli, L	1
Medaglia, M	1
Gismondo, MR	1
Prabhu, RM	1
Elliott, MA	1
Patel, R	1
Preston, SL	1
Fowler, C	1
Corrado, M	1
Weisinger, B	1
Kahn, J	2
Schito, AM	2
Schito, GC	2
Thibodeaux, BA	1
Dajcs, JJ	1
Caballero, AR	1
Marquart, ME	1
Girgis, DO	1
O'Callaghan, RJ	1
Ghelardi, E	1
Tavanti, A	1
Davini, P	1
Celandroni, F	1
Salvetti, S	1
Parisio, E	1
Boldrini, E	1
Senesi, S	1
Campa, M	1
Di Bonaventura, G	1
Picciani, C	1
Spedicato, I	1
Piccolomini, R	1
Rajagopal, AS	1
Lister, PD	1
Wolter, DJ	1
McKnight, AJ	1
Shaw, A	1
Goldsmith, CE	1
Clarke, L	1
Millar, BC	1
McCaughan, J	1
Elborn, JS	1
Reid, A	1
Moore, JE	1
Muramatsu, H	1
Horii, T	1
Takeshita, A	1
Hashimoto, H	1
Maekawa, M	1
Araki-Sasaki, K	1
Nishi, I	1
Yonemura, N	1
Takatsuka, H	1
Mutoh, K	1
Matsumoto, K	2
Asari, S	1
Tanihara, H	1
Piccoli, L	1
Guerrini, M	1
Felici, A	1
Roveta, S	1
Marchese, A	1
Hutschala, D	1
Skhirtladze, K	1
Zuckermann, A	1
Wisser, W	1
Jaksch, P	1
Mayer-Helm, BX	1
Burgmann, H	1
Wolner, E	1
Tschernko, EM	1
Pust, RA	1
Ackenheil-Koppe, HR	1
Gilbert, P	1
Weidner, W	1
Almyroudis, NG	1
Segal, BH	1
Yilmaz, S	1
Saklamaz, A	1
Maden, A	1
Tennenberg, AM	1
Davis, NB	1
Wu, SC	1
Kaye, KS	1
Kanafani, ZA	1
Dodds, AE	1
Engemann, JJ	1
Weber, SG	1
Carmeli, Y	1
Gasink, LB	1
Fishman, NO	1
Weiner, MG	1
Nachamkin, I	1
Bilker, WB	1
Lautenbach, E	1
Epstein, SP	1
Bottone, EJ	1
Asbell, PA	1
Sirvent, E	1
Ruiz, M	1
Rodríguez, JC	1
Royo, G	1
Lee, CKK	1
Boyle, MP	1
Diener-West, M	1
Brass-Ernst, L	1
Noschese, M	1
Zeitlin, PL	1
Topkaya, AE	1
Ozakkaş, F	1
Aksungar, FB	1
Tülbek, Y	1
Segatore, B	1
Perilli, M	1
Larosa, M	1
Setacci, D	1
Celenza, G	1
Amicosante, G	1
Oxley, KS	1
Thomas, JG	1
Ramadan, HH	1
Franco-Vidal, V	1
Blanchet, H	1
Bebear, C	1
Dutronc, H	1
Darrouzet, V	1
Ferrer, C	1
Rodríguez, A	1
Abad, JL	1
Fernandez, J	1
Alió, JL	1
Kobayashi, H	2
Takamura, K	1
Kono, K	1
Onodera, S	1
Sasaki, N	1
Nagahama, F	1
Kawakami, Y	1
Honma, Y	1
Matsuzaki, M	1
Tanimura, K	1
Shiao, S	1
Isobe, Y	1
Hatano, H	1
Ohno, S	1
Høiby, N	3
Pedersen, SS	4
Jensen, T	4
Valerius, NH	1
Koch, C	3
Upton, C	1
Miyagawa, S	1
Kamata, R	1
Okamura, R	1
Maeda, H	1
Regev, G	1
Mouallem, M	1
Reid, G	1
Sharma, S	1
Advikolanu, K	1
Tieszer, C	1
Martin, RA	1
Bruce, AW	1
Yasuda, H	1
Ajiki, Y	1
Koga, T	1
Kawada, H	1
Yokota, T	1
Spivey, IM	1
Gentry, LO	2
Rodriguez-Gomez, G	1
Himmelfarb, MZ	2
Zikk, D	2
Rapoport, Y	2
Redianu, C	2
Shalit, I	2
Klepser, ME	1
Patel, KB	1
Nicolau, DP	1
Quintiliani, R	1
Nightingale, CH	1
Tsuchimori, N	1
Yamazaki, T	1
Okonogi, K	1
Yagel, SK	1
Barrett, JF	1
Amaratunga, DJ	1
Frosco, MB	1
Procope, JA	1
Ishida, H	1
Ishida, Y	2
Kurosaka, Y	1
Otani, T	2
Sato, K	1
Colsky, AS	1
Kirsner, RS	1
Kerdel, FA	1
Krutikov, MG	1
Alekseev, AA	1
Bobrovnikov, AE	1
Grishina, IA	1
Elagina, LV	1
Izotova, GN	1
Iakovlev, VP	1
Peterson, LR	1
Postelnick, M	1
Pozdol, TL	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Efficacy of Three Dosage Regimens of MP-376 Solution for Inhalation Given for 28 Days to Stable CF Patients[NCT00677365]	Phase 2	151 participants (Actual)	Interventional	2008-06-30	Completed
A Randomised Controlled Trial Evaluating a Novel Individualised Treatment Strategy for Carbapenem-Resistant Gram-Negative Bacteria Infections (iACT)[NCT04202861]		594 participants (Anticipated)	Interventional	2019-07-08	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Change in the predicted percent of air the patient could exhale in one second (NCT00677365)
Timeframe: from baseline to the end of the treatment 28-day treatment period (28 days)

Change in P. Aeruginosa Density

Intervention	Percent (Least Squares Mean)
Placebo	-2.39
MP-376 120 mg QD	1.96
MP-376 240 mg QD	3.10
MP-376 240 mg BID	8.55

Patients were required to cough deeply and then spit sputum into a sterile container. The bacteria contained in the sputum sample was incubated in a laboratory and the number of P. aeruginosa colony forming units per gram of sputum (CFU/g) was determined. The difference in CFUs/g were then compared from baseline to the conclusion of the 28 day treatment period (NCT00677365)
Timeframe: from baseline to end of treatment (28 days)

Changes in Respiratory Domain Scores of Cystic Fibrosis Questionnaire - Revised (CFQ-R)

Intervention	log10 CFU/g sputum (Least Squares Mean)
Placebo	0.23
MP-376 120 mg QD	-0.31
MP-376 240 mg QD	-0.31
MP-376 240 mg BID	-0.73

Change in the score from 0 to 100 that a patient reports for their respiratory symptoms in the CFQ-R. An increase in score illustrates an improvement in symptoms. An increase of 4 or more is considered clinically significant (NCT00677365)
Timeframe: from baseline to the end of the 28-day treatment period (28 days)

Percent Change in Forced Expiratory Volume in 1 Second (FEV1)

Intervention	units on a scale (Least Squares Mean)
Placebo	-0.44
MP-376 120 mg QD	2.00
MP-376 240 mg QD	0.31
MP-376 240 mg BID	4.06

Percent change in the amount of air the patient could exhale in 1 second (NCT00677365)
Timeframe: from baseline to end of the 28-day treatment period (28 days)

Time to Administration of Other Anti-pseudomonal Antimicrobials

Intervention	Percent change (Least Squares Mean)
Placebo	-2.36
MP-376 120 mg QD	1.93
MP-376 240 mg QD	2.56
MP-376 240 mg BID	6.25

Time to administration of other anti-pseudomonal antimicrobials in patients with at least one of the following: decreased exercise tolerance, increased cough, increased sputum/chest congestion, or decreased appetite; 25th percentile data reported (NCT00677365)
Timeframe: from baseline until final study visit (up to 56 days)

Changes in Susceptability Patterns of Isolated Organisms

Intervention	days (Mean)
Placebo	31
MP-376 120 mg QD	NA
MP-376 240 mg QD	56
MP-376 240 mg BID	59

All isolates of P. aeruginosa cultures grown from patient sputum samples were evaluated to see whether the minimum concentration of levofloxacin needed to inhibit growth of the bacteria (i.e., minimum inhibitory concentration; MIC) had increased; 2. The MIC50 and MIC90 values were calculated as the 50th percentile value and the 90th percentile value, respectively. Note that percentile values between dilution values were rounded up to the nearest dilution value (NCT00677365)
Timeframe: from baseline until the end of the 28-day treatment period (28 days)

Intervention	ug/mL (Number)
	Baseline Minimum Inhibitory Concentration (MIC)50	Day 28 MIC for 50% (MIC50)	Baseline MIC for 90% (MIC90)	Day 28 MIC90
MP-376 120 mg QD	4	4	32	16
MP-376 240 mg BID	4	4	16	32
MP-376 240 mg QD	4	4	16	16
Placebo	4	4	16	8

Article	Year
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones. Pediatric pulmonology, 2013, Volume: 48, Issue:3 Topics: Administration, Oral; Anti-Bacterial Agents; Ciprofloxacin; Cystic Fibrosis; Disease Progression; Dr	2013
MP-376 (Aeroquin) for chronic Pseudomonas aeruginosa infections. Expert opinion on investigational drugs, 2013, Volume: 22, Issue:2 Topics: Administration, Inhalation; Anti-Bacterial Agents; Chronic Disease; Clinical Trials as Topic; Drug D	2013
Current and future perspectives for levofloxacin in severe Pseudomonas aeruginosa infections. Journal of chemotherapy (Florence, Italy), 2003, Volume: 15, Issue:4 Topics: Anti-Bacterial Agents; Drug Resistance, Microbial; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin	2003
Levofloxacin, a broad spectrum anti-infective: from Streptococcus pneumoniae to Pseudomonas aeruginosa. Journal of chemotherapy (Florence, Italy), 2004, Volume: 16 Suppl 2 Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Humans; Italy; Levofloxacin; Micro	2004
Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience. Current medical research and opinion, 2006, Volume: 22, Issue:5 Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; Community-Acquired Infections; Cross Infection; Drug Re	2006
Fluoroquinolones in the treatment of cystic fibrosis. Drugs, 1993, Volume: 45 Suppl 3 Topics: Ciprofloxacin; Cystic Fibrosis; Drug Therapy, Combination; Humans; Ofloxacin; Pseudomonas Infections	1993
Ofloxacin, a bactericidal antibacterial. Chemotherapy, 1991, Volume: 37 Suppl 1 Topics: Anti-Infective Agents; Bacteria; DNA, Bacterial; Drug Resistance, Microbial; Escherichia coli; Human	1991

Article	Year
Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. American journal of respiratory and critical care medicine, 2011, Jun-01, Volume: 183, Issue:11 Topics: Administration, Inhalation; Adult; Anti-Bacterial Agents; Cystic Fibrosis; Dose-Response Relationshi	2011
[Multicentric study for evaluation of levofloxacin in the treatment of complicated urinary tract infections]. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 2003, Volume: 75, Issue:1 Topics: Anti-Infective Agents; Drug Administration Schedule; Drug Resistance, Bacterial; Enterobacteriaceae	2003
Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosa. The Journal of antimicrobial chemotherapy, 2003, Volume: 52, Issue:3 Topics: Aged; Anti-Bacterial Agents; Area Under Curve; Drug Resistance, Bacterial; Female; Fluoroquinolones;	2003
Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. The Journal of infectious diseases, 2004, May-01, Volume: 189, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Area Under Curve; Cross Infection; Female; Fl	2004
Levofloxacin pharmacokinetics in adult cystic fibrosis. Chest, 2007, Volume: 131, Issue:3 Topics: Adolescent; Adult; Anti-Bacterial Agents; Cystic Fibrosis; Female; Humans; Kidney Function Tests; Le	2007
[Comparison of DL-8280 and amoxicillin in the treatment of respiratory tract infections]. Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases, 1984, Volume: 58, Issue:6 Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bronchiectasis; Bronchitis; Clinical Trials as Topi	1984
Ofloxacin treatment of difficult infections of the skin and skin structure. Cutis, 1993, Volume: 51, Issue:1 Topics: Abscess; Administration, Oral; Adult; Aged; Aged, 80 and over; Cellulitis; Drug Administration Sched	1993
Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy, 1995, Volume: 39, Issue:11 Topics: Adult; Anti-Infective Agents; Ceftazidime; Cephalosporins; Ciprofloxacin; Cross-Over Studies; Drug R	1995
[Efficacy of lomefloxacin and ofloxacin in complex therapy of infections in patients with burns]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 1998, Volume: 43, Issue:10 Topics: Adolescent; Adult; Anti-Infective Agents; Burns; Drug Resistance, Microbial; Drug Resistance, Multip	1998
[The use of ofloxacin in cystic fibrosis patients]. Minerva pediatrica, 1992, Volume: 44, Issue:3 Topics: Adolescent; Adult; Analysis of Variance; Chronic Disease; Cystic Fibrosis; Drug Tolerance; Female; H	1992
Oral ofloxacin for infections caused by bacteria resistant to oral antimicrobial agents. Diagnostic microbiology and infectious disease, 1992, Volume: 15, Issue:5 Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Diabetes Complications; Drug Resistance, Mi	1992
[A cross-over study on the effectiveness of ofloxacin and ciprofloxacin administered orally]. Infection, 1986, Volume: 14 Suppl 1 Topics: Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Ciprofloxacin; Clinical Trials as To	1986
Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis. European journal of clinical microbiology, 1987, Volume: 6, Issue:6 Topics: Adult; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Clinical Trials as Topic; Cystic Fibro	1987
Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. The Journal of antimicrobial chemotherapy, 1987, Volume: 20, Issue:4 Topics: Adolescent; Adult; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Double-Blind Method; Femal	1987
The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. The Journal of antimicrobial chemotherapy, 1987, Volume: 20, Issue:4 Topics: Adolescent; Adult; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Double-Blind Method; Drug	1987

Article	Year
Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids. Journal of medicinal chemistry, 1992, Dec-11, Volume: 35, Issue:25 Topics: Administration, Oral; Animals; Anti-Infective Agents; Carboxylic Acids; Escherichia coli Infections;	1992
Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. Journal of medicinal chemistry, 1990, Volume: 33, Issue:6 Topics: 4-Quinolones; Animals; Anti-Infective Agents; Drug Interactions; Fluoroquinolones; Male; Mice; Micro	1990
Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:5 Topics: Aminoglycosides; Anti-Bacterial Agents; Carbenicillin; Ceftazidime; Ciprofloxacin; Drug Resistance,	2008
Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:11 Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Outer Membrane Proteins; Down-Regulation; Humans; Mac	2008
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:10 Topics: Base Sequence; beta-Lactam Resistance; Carbapenems; DNA Primers; DNA, Bacterial; Doripenem; Fluoroqu	2008
Treatment with a neutrophil elastase inhibitor and ofloxacin reduces P. aeruginosa burden in a mouse model of chronic suppurative otitis media. NPJ biofilms and microbiomes, 2021, 04-06, Volume: 7, Issue:1 Topics: Animals; Antigens, Ly; Disease Models, Animal; Drug Synergism; Female; Flow Cytometry; Humans; Machi	2021
Development of a novel biodegradable drug-eluting ventilation tube for chronic otitis media with effusion. The Laryngoscope, 2013, Volume: 123, Issue:7 Topics: Animals; Coated Materials, Biocompatible; Guinea Pigs; Lactic Acid; Middle Ear Ventilation; Ofloxaci	2013
Recent cluster of childhood microbial keratitis due to orthokeratology. Clinical & experimental ophthalmology, 2014, Volume: 42, Issue:8 Topics: Acanthamoeba Keratitis; Adolescent; Anti-Bacterial Agents; Biguanides; Cephalothin; Child; Chlorhexi	2014
Microparticle-loaded neonatal porcine Sertoli cells for cell-based therapeutic and drug delivery system. Journal of controlled release : official journal of the Controlled Release Society, 2014, Oct-28, Volume: 192 Topics: Animals; Anti-Bacterial Agents; Cells, Cultured; Cryopreservation; Drug Delivery Systems; Male; Oflo	2014
Extensively and pan-drug resistant Pseudomonas aeruginosa keratitis: clinical features, risk factors, and outcome. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2016, Volume: 254, Issue:2 Topics: Anti-Bacterial Agents; Ciprofloxacin; Colistin; Corneal Ulcer; Drug Resistance, Multiple, Bacterial;	2016
Occurrence and antibacterial susceptibility pattern of bacterial pathogens isolated from diarrheal patients in Pakistan. Saudi medical journal, 2016, Volume: 37, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Bacillus cereus; Cef	2016
Antibiotic Sensitivity pattern of Bacterial Isolates of Neonatal Septicemia in Peshawar, Pakistan. Archives of Iranian medicine, 2016, Volume: 19, Issue:12 Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacteri	2016
Siderophores as drug delivery agents: application of the "Trojan Horse" strategy. Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine, 2009, Volume: 22, Issue:4 Topics: Animals; Anti-Bacterial Agents; Drug Delivery Systems; Enterobactin; Humans; Mice; Molecular Structu	2009
[Bacterial corneal ulcer treated with intrastromal antibiotic. Experimental model in vivo]. Archivos de la Sociedad Espanola de Oftalmologia, 2009, Volume: 84, Issue:3 Topics: Analysis of Variance; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cornea;	2009
Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:8 Topics: Animals; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Epithelium; Fe	2009
A recent evaluation of empirical cephalosporin treatment and antibiotic resistance of changing bacterial profiles in spontaneous bacterial peritonitis. Digestive diseases and sciences, 2010, Volume: 55, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ascitic Fluid; Bacterial Infections; Cefepime	2010
Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:9 Topics: Administration, Inhalation; Aerosols; Animals; Anti-Bacterial Agents; Aztreonam; Disease Models, Ani	2009
Fluoroquinolone-resistant Pseudomonas aeruginosa in chronic rhinosinusitis. ORL; journal for oto-rhino-laryngology and its related specialties, 2009, Volume: 71, Issue:5 Topics: Anti-Bacterial Agents; Chronic Disease; Ciprofloxacin; Comorbidity; Drug Resistance, Bacterial; Fluo	2009
Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients. Diagnostic microbiology and infectious disease, 2010, Volume: 66, Issue:2 Topics: Aerobiosis; Aerosols; Anaerobiosis; Anti-Bacterial Agents; Cystic Fibrosis; Humans; Levofloxacin; Mi	2010
Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use. International journal of antimicrobial agents, 2010, Volume: 35, Issue:3 Topics: Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Drug Utilization;	2010
The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:6 Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Colony Count, Microbial; Drug Resistance,	2010
Topical levofloxacin 1.5% overcomes in vitro resistance in rabbit keratitis models. Acta ophthalmologica, 2010, Volume: 88, Issue:4 Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Cefazolin; Ciprofloxacin; Colony Count, Mic	2010
Ecthyma gangrenosum mimicking acute invasive fungal sinusitis in an immunocompromised patient. Ear, nose, & throat journal, 2010, Volume: 89, Issue:6 Topics: Acetamides; Adult; Anti-Bacterial Agents; Diagnosis, Differential; Ecthyma; Humans; Immunocompromise	2010
Novel in vitro pharmacodynamic model simulating ofloxacin pharmacokinetics in the treatment of Pseudomonas aeruginosa biofilm-associated infections. Journal of infection and public health, 2009, Volume: 2, Issue:3 Topics: Anti-Bacterial Agents; Biofilms; Bioreactors; Microbial Sensitivity Tests; Microscopy, Electron, Sca	2009
In vivo quantification of bacterial keratitis with optical coherence tomography. Investigative ophthalmology & visual science, 2011, Feb-25, Volume: 52, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefuroxime; Cornea; Corneal Ulcer; Drug Monit	2011
Enhanced bacterial uptake and bactericidal properties of ofloxacin loaded on bioadhesive hydrogels against Pseudomonas aeruginosa. Journal of chemotherapy (Florence, Italy), 2010, Volume: 22, Issue:5 Topics: Acrylic Resins; Adhesiveness; Anti-Bacterial Agents; Ciprofloxacin; Fluoroquinolones; Humans; Hydrog	2010
Evaluation by Monte Carlo simulation of levofloxacin dosing for complicated urinary tract infections caused by Escherichia coli or Pseudomonas aeruginosa. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2011, Volume: 17, Issue:5 Topics: Anti-Bacterial Agents; Area Under Curve; Computer Simulation; Databases, Factual; Escherichia coli;	2011
Risk factors for bacteraemia attributable to Pseudomonas aeruginosa resistant to imipenem, levofloxacin, or gentamicin. The Journal of hospital infection, 2011, Volume: 79, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Child; Child, Prescho	2011
Autologous fascia lata grafts for scleral repair in eyes with infectious necrotizing scleritis. Archives of ophthalmology (Chicago, Ill. : 1960), 2011, Volume: 129, Issue:9 Topics: Aged; Amnion; Ceftazidime; Eye Infections, Bacterial; Eye Infections, Fungal; Fascia Lata; Female; H	2011
Prevalence of efflux-mediated ciprofloxacin and levofloxacin resistance in recent clinical isolates of Pseudomonas aeruginosa and its reversal by the efflux pump inhibitors 1-(1-naphthylmethyl)-piperazine and phenylalanine-arginine-β-naphthylamide. International journal of antimicrobial agents, 2012, Volume: 39, Issue:1 Topics: Anti-Bacterial Agents; Ciprofloxacin; Dipeptides; Drug Resistance, Multiple, Bacterial; Fluoroquinol	2012
Infectious mid basilar artery aneurysm from Pseudomonas meningitis. Journal of neurointerventional surgery, 2012, Volume: 4, Issue:3 Topics: Adult; Angiography, Digital Subtraction; Anti-Bacterial Agents; Carotid Artery, Internal, Dissection	2012
Active starvation responses mediate antibiotic tolerance in biofilms and nutrient-limited bacteria. Science (New York, N.Y.), 2011, Nov-18, Volume: 334, Issue:6058 Topics: Animals; Anti-Bacterial Agents; Biofilms; Catalase; Drug Resistance, Bacterial; Drug Tolerance; Esch	2011
Effective antibiotics in combination against extreme drug-resistant Pseudomonas aeruginosa with decreased susceptibility to polymyxin B. PloS one, 2011, Volume: 6, Issue:12 Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamases; Drug Resistance, Bacterial; Drug Synergism; Drug T	2011
A peptide based on homologous sequences of the β-barrel assembly machinery component BamD potentiates antibiotic susceptibility of Pseudomonas aeruginosa. The Journal of antimicrobial chemotherapy, 2012, Volume: 67, Issue:9 Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Bacterial Outer Membrane Proteins; Blotting, Western	2012
Community acquired Pseudomonas pneumonia in an immune competent host. BMJ case reports, 2012, May-26, Volume: 2012 Topics: Adult; Anti-Bacterial Agents; Biopsy; Community-Acquired Infections; Diagnosis, Differential; Humans	2012
In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients. International journal of antimicrobial agents, 2012, Volume: 40, Issue:2 Topics: Bacterial Typing Techniques; Biofilms; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Levofloxacin;	2012
Persister eradication: lessons from the world of natural products. Methods in enzymology, 2012, Volume: 517 Topics: Anti-Bacterial Agents; Biofilms; Biological Products; Drug Resistance, Multiple, Bacterial; Humans;	2012
The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains. International journal of antimicrobial agents, 2002, Volume: 20, Issue:5 Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combinatio	2002
[Effects of the zhikuofang on the inflammation and cytostatics of the airway model of bronchiectasis]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2002, Volume: 27, Issue:2 Topics: Animals; Anti-Infective Agents; Bronchiectasis; Bronchitis; Drug Combinations; Drugs, Chinese Herbal	2002
In vitro evaluation of the activity of two doses of Levofloxacin alone and in combination with other agents against Pseudomonas aeruginosa. Diagnostic microbiology and infectious disease, 2003, Volume: 46, Issue:2 Topics: Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Drug Synergism; Evaluation Studies as	2003
Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. The Journal of clinical investigation, 2003, Volume: 112, Issue:2 Topics: Animals; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Drug R	2003
A comparison of invasive and cytotoxic Pseudomonas aeruginosa strain-induced corneal disease responses to therapeutics. Current eye research, 2003, Volume: 27, Issue:5 Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Cornea; Corneal Ulcer; Disease Models, Anim	2003
Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis. Antimicrobial agents and chemotherapy, 2003, Volume: 47, Issue:11 Topics: Aged; Anti-Infective Agents; Area Under Curve; Blood Proteins; Drug Delivery Systems; Female; Humans	2003
Treatment of experimental bacterial keratitis with topical trovafloxacin. Archives of ophthalmology (Chicago, Ill. : 1960), 2004, Volume: 122, Issue:1 Topics: Administration, Topical; Animals; Anti-Infective Agents; Biological Availability; Ciprofloxacin; Col	2004
Factors influencing fluoroquinolone resistance. Emerging infectious diseases, 2003, Volume: 9, Issue:12 Topics: Anti-Infective Agents; Area Under Curve; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Microbia	2003
[Resistance of Pseudomonas aeruginosa to ciprofloxacin and levofloxacin: 1998-2002]. Le infezioni in medicina, 2003, Volume: 11, Issue:4 Topics: Body Fluids; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Levofloxacin; Ofloxacin; Pseudomonas	2003
Apparent failure of moxifloxacin to prevent ciprofloxacin- and levofloxacin-susceptible Pseudomonas aeruginosa bacteremia in neutropenic patients undergoing peripheral blood stem cell transplantation. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Apr-01, Volume: 38, Issue:7 Topics: Anti-Infective Agents; Aza Compounds; Bacteremia; Ciprofloxacin; Female; Fluoroquinolones; Hematopoi	2004
Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis. Current eye research, 2004, Volume: 28, Issue:5 Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Cornea; Eye I	2004
A mucoadhesive polymer extracted from tamarind seed improves the intraocular penetration and efficacy of rufloxacin in topical treatment of experimental bacterial keratitis. Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:9 Topics: Adhesives; Administration, Topical; Animals; Anti-Bacterial Agents; Chemistry, Pharmaceutical; Colon	2004
E-test method for detecting antibiotic synergy against Pseudomonas aeruginosa from neutropenic patients: a cost-effective approach. The new microbiologica, 2004, Volume: 27, Issue:3 Topics: Anemia; Anti-Bacterial Agents; Cefotaxime; Ceftriaxone; Cost-Benefit Analysis; Drug Synergism; Drug	2004
Pseudomonas orchitis in puberty. International journal of STD & AIDS, 2004, Volume: 15, Issue:10 Topics: Adolescent; Anti-Bacterial Agents; Diagnosis, Differential; Humans; Male; Ofloxacin; Orchitis; Pseud	2004
Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2005, Feb-15, Volume: 40 Suppl 2 Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Comb	2005
Comparison of in vitro susceptibilities to levofloxacin and ciprofloxacin with Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients in Northern Ireland. British journal of biomedical science, 2005, Volume: 62, Issue:1 Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Child; Ciprofloxacin; Cystic Fibrosis; Female;	2005
Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant Pseudomonas aeruginosa. Chemotherapy, 2005, Volume: 51, Issue:2-3 Topics: Anti-Bacterial Agents; Carbapenems; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fl	2005
Characteristics of Pseudomonas corneal infection related to orthokeratology. Cornea, 2005, Volume: 24, Issue:7 Topics: Administration, Topical; Adolescent; Anti-Bacterial Agents; Cefmenoxime; Cefozopran; Cephalosporins;	2005
In vitro and in vivo synergy of levofloxacin or amikacin both in combination with ceftazidime against clinical isolates of Pseudomonas aeruginosa. Journal of chemotherapy (Florence, Italy), 2005, Volume: 17, Issue:4 Topics: Amikacin; Animals; Ceftazidime; Disease Models, Animal; Drug Resistance, Bacterial; Drug Synergism;	2005
Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa. International journal of antimicrobial agents, 2005, Volume: 26, Issue:5 Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cystic Fibrosis; Dioxolanes; Drug Resistance, B	2005
In vivo measurement of levofloxacin penetration into lung tissue after cardiac surgery. Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:12 Topics: Aged; Anti-Infective Agents; Area Under Curve; Coronary Artery Bypass; Dose-Response Relationship, D	2005
Clinical efficacy of ofloxacin (tarivid) in patients with chronic bacterial prostatitis: preliminary results. Journal of chemotherapy (Florence, Italy), 1989, Volume: 1, Issue:4 Suppl Topics: Adult; Anti-Infective Agents; Bacterial Infections; Clinical Trials as Topic; Escherichia coli Infec	1989
Antibacterial prophylaxis in patients with cancer and neutropenia. The New England journal of medicine, 2006, Jan-05, Volume: 354, Issue:1 Topics: Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Drug Resistance, Bacteri	2006
Pseudomonas keratitis. Ophthalmology, 2006, Volume: 113, Issue:5 Topics: Adolescent; Anti-Bacterial Agents; Cornea; Corneal Ulcer; Drug Therapy, Combination; Eye Infections,	2006
Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:6 Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Case-Control Studies; Ciprofloxacin; Cross Infection	2006
Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. The American journal of medicine, 2006, Volume: 119, Issue:6 Topics: Academic Medical Centers; Case-Control Studies; Cohort Studies; Cross Infection; Drug Resistance, Ba	2006
Susceptibility testing of clinical isolates of pseudomonas aeruginosa to levofloxacin, moxifloxacin, and gatifloxacin as a guide to treating pseudomonas ocular infections. Eye & contact lens, 2006, Volume: 32, Issue:5 Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacteria	2006
[Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration]. Enfermedades infecciosas y microbiologia clinica, 2006, Volume: 24, Issue:10 Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Dr	2006
[A case of urinary tract infection caused by Flavimonas oryzihabitans]. Mikrobiyoloji bulteni, 2007, Volume: 41, Issue:1 Topics: Anti-Infective Agents, Urinary; Bacteriuria; Carbapenems; Drug Resistance, Multiple, Bacterial; Fema	2007
An in vitro investigation of levofloxacin and ciprofloxacin against clinical isolates of Pseudomonas aeruginosa. International journal of antimicrobial agents, 2007, Volume: 30, Issue:4 Topics: Anti-Bacterial Agents; Ciprofloxacin; Humans; Italy; Levofloxacin; Microbial Sensitivity Tests; Oflo	2007
Effect of ototopical medications on tympanostomy tube biofilms. The Laryngoscope, 2007, Volume: 117, Issue:10 Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Biofilms; Ciprofloxacin; Dexamethasone; Drug Admini	2007
Necrotizing external otitis: a report of 46 cases. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2007, Volume: 28, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Diabetes Complications; Facial Paralysis; Fem	2007
Bactericidal effect of intravitreal levofloxacin in an experimental model of endophthalmitis. The British journal of ophthalmology, 2008, Volume: 92, Issue:5 Topics: Animals; Anti-Bacterial Agents; Ceftazidime; Endophthalmitis; Female; Levofloxacin; Male; Microbial	2008
Comparative study on topical and oral administration of ofloxacin for Pseudomonas corneal ulcer in rabbits. Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 1995, Volume: 209, Issue:3 Topics: Administration, Oral; Administration, Topical; Animals; Cornea; Corneal Ulcer; Eye Infections, Bacte	1995
Sleep disturbance in children treated with ofloxacin. BMJ (Clinical research ed.), 1994, Nov-26, Volume: 309, Issue:6966 Topics: Child; Cystic Fibrosis; Female; Humans; Male; Ofloxacin; Opportunistic Infections; Pseudomonas Infec	1994
Therapeutic intervention with chicken egg white ovomacroglobulin and a new quinolone on experimental Pseudomonas keratitis. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 1994, Volume: 232, Issue:8 Topics: alpha-Macroglobulins; Animals; Cathepsin G; Cathepsins; Egg Proteins, Dietary; Eye Infections, Bacte	1994
[Acute suppurative parotitis caused by Pseudomonas aeruginosa]. Harefuah, 1994, Volume: 127, Issue:3-4 Topics: Acute Disease; Aged; Clindamycin; Drug Therapy, Combination; Female; Gentamicins; Humans; Ofloxacin;	1994
Effects of ciprofloxacin, norfloxacin, and ofloxacin on in vitro adhesion and survival of Pseudomonas aeruginosa AK1 on urinary catheters. Antimicrobial agents and chemotherapy, 1994, Volume: 38, Issue:7 Topics: Anti-Infective Agents; Bacterial Adhesion; Biofilms; Chromatography, High Pressure Liquid; Ciproflox	1994
Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin. Antimicrobial agents and chemotherapy, 1993, Volume: 37, Issue:9 Topics: Alginates; Animals; Bacterial Proteins; Clarithromycin; Filtration; Hexoses; Male; Microbial Sensiti	1993
Criteria for use of ofloxacin and lomefloxacin in adult inpatients and outpatients. Clinical pharmacy, 1993, Volume: 12, Issue:6 Topics: Adult; Anti-Infective Agents; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Infectio	1993
Granulation tissue concentrations of ofloxacin after oral administration in invasive external otitis. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 1993, Volume: 250 Suppl 1 Topics: Administration, Oral; Aged; Female; Granulation Tissue; Humans; Male; Middle Aged; Ofloxacin; Otitis	1993
Therapeutic effects of cefozopran against experimental mixed urinary tract infection with Enterococcus faecalis and Pseudomonas aeruginosa in mice. The Journal of antimicrobial chemotherapy, 1997, Volume: 39, Issue:3 Topics: Ampicillin; Animals; Cefozopran; Ceftazidime; Cephalosporins; Cilastatin; Enterococcus faecalis; Fem	1997
In vivo oral efficacy of levofloxacin for treatment of systemic Pseudomonas aeruginosa infections in a murine model of septicemia. Antimicrobial agents and chemotherapy, 1996, Volume: 40, Issue:12 Topics: Administration, Oral; Animals; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Female; Levofloxaci	1996
Delayed-onset Pseudomonas keratitis after radial keratotomy. Journal of cataract and refractive surgery, 1997, Volume: 23, Issue:8 Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; Astigmatism; Cornea; Corneal Ulc	1997
In vitro and in vivo activities of levofloxacin against biofilm-producing Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy, 1998, Volume: 42, Issue:7 Topics: Alginates; Animals; Anti-Infective Agents; Biofilms; Female; Glucuronic Acid; Guinea Pigs; Hexuronic	1998
Analysis of antibiotic susceptibilities of skin wound flora in hospitalized dermatology patients. The crisis of antibiotic resistance has come to the surface. Archives of dermatology, 1998, Volume: 134, Issue:8 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Dermatitis; Drug Resistance, Microbial;	1998
Management of fluoroquinolone resistance in Pseudomonas aeruginosa--outcome of monitored use in a referral hospital. International journal of antimicrobial agents, 1998, Volume: 10, Issue:3 Topics: Anti-Infective Agents; Ciprofloxacin; Disease Management; Drug Monitoring; Drug Resistance, Microbia	1998
Evaluation of post-antibiotic effects of antipseudomonal antibiotics using an automated system. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2000, Volume: 108, Issue:4 Topics: 4-Quinolones; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Automation; Ceftazidime; Cipro	2000
Combination therapy for chronic Pseudomonas aeruginosa respiratory infection associated with biofilm formation. The Journal of antimicrobial chemotherapy, 2000, Volume: 46, Issue:1 Topics: Animals; Biofilms; Chronic Disease; Clarithromycin; Disease Models, Animal; Drug Therapy, Combinatio	2000
A 14-year-old boy with kidney allograft failure in the first month after transplantation. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2000, Volume: 36, Issue:4 Topics: Acute Disease; Adolescent; Anti-Infective Agents, Urinary; Biopsy; Creatinine; Diagnosis, Differenti	2000
Fluoroquinolone pharmacodynamics: prospective determination of relationships between exposure and outcome. Journal of chemotherapy (Florence, Italy), 2000, Volume: 12 Suppl 4 Topics: Animals; Anti-Infective Agents; Area Under Curve; Dose-Response Relationship, Drug; Drug Administrat	2000
Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different! Diagnostic microbiology and infectious disease, 2001, Volume: 41, Issue:3 Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Urinary; Cipro	2001
Infectious keratitis in orthokeratology. Clinical & experimental ophthalmology, 2002, Volume: 30, Issue:1 Topics: Acanthamoeba Keratitis; Adult; Antiprotozoal Agents; Astigmatism; Benzamidines; Chloramphenicol; Con	2002
Investigation into the selection frequency of resistant mutants and the bacterial kill rate by levofloxacin and ciprofloxacin in non-mucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients. International journal of antimicrobial agents, 2002, Volume: 19, Issue:5 Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug	2002
Anti-inflammatory therapy and outcome in a guinea pig model of Pseudomonas keratitis. Cornea, 1992, Volume: 11, Issue:5 Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dicarboxylic Acids; Disease	1992
Peritonitis caused by Pseudomonas putrefaciens in patients undergoing continuous ambulatory peritoneal dialysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1992, Volume: 14, Issue:1 Topics: Aged; Female; Gentamicins; Humans; Middle Aged; Ofloxacin; Peritoneal Dialysis, Continuous Ambulator	1992
Topical ofloxacin in the treatment of Pseudomonas keratitis in a rabbit model. Cornea, 1992, Volume: 11, Issue:2 Topics: Administration, Topical; Animals; Aqueous Humor; Chromatography, High Pressure Liquid; Disease Model	1992
[Pseudomonas aeruginosa ocular infection]. Nihon rinsho. Japanese journal of clinical medicine, 1991, Volume: 49, Issue:10 Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Drug Resistance, Microbial; Eye Infections, Bacteria	1991
Oral ofloxacin therapy for invasive external otitis. The Annals of otology, rhinology, and laryngology, 1991, Volume: 100, Issue:8 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Diabetes Complications; Drug Administration Sc	1991
Oral aminoglycoside and ofloxacin therapy in the prevention of gram-negative sepsis after irradiation. The Journal of infectious diseases, 1991, Volume: 164, Issue:5 Topics: Administration, Oral; Animals; Female; Gamma Rays; Gentamicins; Immunity; Injections, Intramuscular;	1991
[Activity of fluoroquinolones studied on a model of suppurative meningoencephalitis caused by Pseudomonas aeruginosa in mice]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 1991, Volume: 36, Issue:7 Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Microbial; E	1991
Oral ofloxacin therapy of Pseudomonas aeruginosa sepsis in mice after irradiation. Antimicrobial agents and chemotherapy, 1990, Volume: 34, Issue:7 Topics: Animals; Cobalt Radioisotopes; Female; Ileum; Liver; Mice; Mice, Inbred Strains; Microbial Sensitivi	1990
[Local treatment of Pseudomonas aeruginosa infection of the external ear canal with the gyrase inhibitor Tarivid]. Laryngo- rhino- otologie, 1989, Volume: 68, Issue:11 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Ofloxacin; Otitis Ext	1989
Chemotherapeutic efficacy of ofloxacin against experimental pneumonia with Pseudomonas aeruginosa in guinea pigs. Arzneimittel-Forschung, 1989, Volume: 39, Issue:6 Topics: Animals; Disease Models, Animal; Female; Guinea Pigs; Immunosuppression Therapy; Lung; Ofloxacin; Pn	1989
A prospective study of ofloxacin in acute exacerbations of chronic respiratory disease associated with Pseudomonas aeruginosa. The Journal of antimicrobial chemotherapy, 1989, Volume: 24, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Lung Diseases, Obstructive; Male; Middle	1989
[New oral quinolone compounds in chronic bronchitis]. Infection, 1986, Volume: 14 Suppl 1 Topics: Administration, Oral; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Chronic Disease; Cipr	1986
Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa pneumonia. Antimicrobial agents and chemotherapy, 1986, Volume: 29, Issue:3 Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Enoxacin; Guinea Pigs; Kinetics; Naphthyridines; Oflo	1986
Ofloxacin therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa. The Journal of infectious diseases, 1987, Volume: 155, Issue:4 Topics: Animals; Anti-Bacterial Agents; Bone and Bones; Ofloxacin; Osteomyelitis; Oxazines; Pseudomonas aeru	1987
[Ofloxacin in the treatment of Pseudomonas aeruginosa infections of the ear]. HNO, 1988, Volume: 36, Issue:6 Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Ofloxacin; Otitis; Otitis Externa; Otitis Media; Oxa	1988
[Bone infections: treatment by ofloxacin. Apropos of 10 cases]. Pathologie-biologie, 1987, Volume: 35, Issue:5 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Enterobacteriaceae Infections;	1987
Ofloxacin: therapeutic activity in experimental infections. Chemioterapia : international journal of the Mediterranean Society of Chemotherapy, 1986, Volume: 5, Issue:6 Topics: Administration, Oral; Agranulocytosis; Animals; Anti-Infective Agents; Female; Male; Mice; Ofloxacin	1986
Comparative activity of ofloxacin with reference to bacterial strains isolated in in-patients and out-patients. Infection, 1986, Volume: 14 Suppl 1 Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Cross Infection; Dose-Response Relationship,	1986
[Results of ofloxacin treatment of experimental urinary tract infections]. Infection, 1986, Volume: 14 Suppl 1 Topics: Animals; Anti-Infective Agents, Urinary; Dose-Response Relationship, Drug; Escherichia coli Infectio	1986

ofloxacin and Pseudomonas Infections